HOME >> BIOLOGY >> NEWS
PTEN and prostate cancer--the devil is in the doses

Cancer is a complex disease where multiple genetic and environmental factors contribute to risk. Its onset and progression depends on the combination of a series of genetic disruptions rather than on a single event. At a genetic level, it is not just presence or absence of a gene (or a mutated version of the gene) that causes disease, but as Pier Paolo Pandolfi and colleagues report, protein "dose"--that is, the level of remaining activity--also influences cancer progression.

Focusing on the tumor suppressor gene PTEN, the researchers created a mouse model system to study tumor progression in prostate cancer. PTEN is among the most commonly mutated tumor suppressor genes in human cancer. And like many other tumor suppressors, PTEN targets proteins in signaling pathways that regulate cell growth and apoptosis in healthy tissue and contributes to cancer when dysfunctional. Humans, as diploid organisms, generally have two versions of most genes, including PTEN. In the event that one copy is damaged or lost, gene function is usually maintained by the other copy. In the classic definition of a tumor suppressor, both copies must be lost for a tumor to occur. Yet in many cases of advanced cancer, including prostate cancer, only one copy is lost at the time a patient shows symptoms. It is then not unreasonable to hypothesize that the degree of remaining PTEN activity controls the course of the disease: loss of one copy could influence tumor initiation, while further slight reductions might be sufficient to facilitate the invasion and metastatic behavior of late-stage cancers.

Pandolfi and colleagues chose two strategies to investigate this hypothesis. In the first approach, they genetically engineered one series of mice with minimal levels of murine PTEN protein (complete loss results in embryo death). This novel 25%35% active PTEN "hypomorphic" strain of mice, which appears to retain the minimum level of PTEN needed to survive embryonic development, adds
'"/>

Contact: Barbara Cohen
bcohen@plos.org
415-624-1206
Public Library of Science
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
2. Researchers identify distinctive signature for metastatic prostate cancer
3. Charting the future in prostate cancer care: A call to action
4. Study reveals first genetic step necessary for prostate cancer growth
5. Study narrows search for genes placing men at increased risk for prostate cancer
6. MICs shed light on prostate cancer
7. Alterations in vitamin D receptor gene increase prostate, breast cancer risk
8. New prostate cancer gene identified
9. U-M scientists find common virus in human prostate tissue
10. Newly designed nanoparticle quantum dots simultaneously target and image prostate tumors in mice
11. Gene expression patterns may help predict risk and progression of prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... , ... August 06, 2020 , ... ... participate in the prestigious National STEM Scholar Program, a unique professional development program ... and project support for middle school science teachers nationwide. , Created in partnership ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/10/2020)... CHURCH, Va. (PRWEB) , ... July 08, 2020 ... ... The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July ... may need a comparability study, but what is the most effective way to ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and ... a great surgery is only the beginning of a successful study, while protecting and ... Join Brad Gien, Global Head of Surgery from Envigo in a ...
(Date:7/10/2020)... Va. (PRWEB) , ... July 08, 2020 , ... ... testing services and products, announces a significant expansion of laboratory operations through its ... collection for agencies implementing testing programs. , Bode-CARES provides a ...
(Date:7/7/2020)... ... 2020 , ... R3 International is now offering stem cell therapy for Alzheimers ... Depending on the patient's condition, treatment may be offered IV, intrathecal or with a ... of Alzheimers dementia, and the incidence continues to increase as individuals live longer. There ...
Breaking Biology Technology:
Cached News: